Skip to main content

Table 3 Studies that were included in the network meta-analysis

From: Comparative efficacy of statins, metformin, spironolactone and combined oral contraceptives in reducing testosterone levels in women with polycystic ovary syndrome: a network meta-analysis of randomized clinical trials

AuthorYearCountryFollow-up periodDesign for the studynAge (yr.)BMI (Kg/m2)InterventionControl
Ganie et al. [3]2004India6 monthsRandomized open-labelled clinical trial6917.6–28.520.9–32.1Spironolactone (n = 34)Metformin(n = 35)
Hoeger et al. [4]2008USA24 weeksRandomized clinical trial4313.7–17.727.8–46.0Metformin (n = 10),
COC (n = 11), or
lifestyle modification (n = 11)
Placebo (n = 11)
Sathyapalan et al. [5]2009UK12 weeksRandomized double-blind clinical trial3726.3–29.131.8–35.4Atorvastatin (n = 19)Placebo (n = 18)
Kazerooni et al. [1]2010Iran12 weeksRandomized double-blind clinical trial8419.1–30.727.3–30.3Metformin + Simvastatin (n = 42)Metformin + Placebo (n = 42)
Romualdi et al. [6].2010Italy6 monthsRandomized double-blind clinical trial2820.3–29.818.4–26.2Metformin (n = 15)Placebo (n = 13)
Teede et al. [7]2010Australia6 monthsRandomized clinical trial6626.8–40.234.3–37.8Metformin (n = 36)COCs (n = 30)
Raja-Khan et al. [8]2011USA6 weeksRandomized double-blind clinical trial2023.6–38.125.6–51.9Atorvastatin (n = 9)Placebo (n = 11)
Banaszewska et al. [2]2011Poland6 monthsRandomized open-labelled clinical trial9724.7–26.922.9–25.6Simvastatin + Metformin (n = 36)Simvastatin (n = 28) or
Metformin (n = 33)
Ganie et al. [9]2013India6 monthsRandomized open-labelled clinical trial16917.2–28.820.0–30.1Spironolactone + Metformin (n = 62)Spironolactone (n = 51) or Metformin (n = 56)